How Tempus AI cuts cancer treatment time by 70% in 2026: What the evidence actually shows—and how to operationalize the real gains with AI automation

“How Tempus AI cuts cancer treatment time by 70% in 2026” is the kind of headline that spreads fast—because every oncology team and health system want...

Kevan Shah · · 12 min read

“How Tempus AI cuts cancer treatment time by 70% in 2026” is the kind of headline that spreads fast—because every oncology team and health system wants faster diagnoses, fewer delays, and earlier therapy starts. But when you look for a reputable, verifiable source that confirms Tempus achieved a 70% reduction in cancer treatment time in 2026, the evidence isn’t there.

In fact, no evidence exists in available sources confirming that Tempus AI cuts cancer treatment time by 70% in 2026. What does exist—across Tempus oncology materials, press releases, and independent commentary—is a set of AI-enabled capabilities that target the real bottlenecks that slow cancer care: trial onboarding and enrollment, biomarker identification, pathology workflow efficiency, and the transformation of unstructured clinical data into actionable insights. These can reduce delays by days to weeks in specific steps, and they can compound across a patient journey. But the specific “70%” figure, and the tie to 2026, appears unsubstantiated by current reporting.

This post unpacks what Tempus has publicly documented, what it implies technically, and—most importantly—how healthcare, life sciences, and digital health teams can translate these patterns into measurable cycle-time reductions using AI consulting and workflow automation (including n8n workflows) without over-claiming outcomes.

How Tempus AI cuts cancer treatment time by 70% in 2026 (and why that claim needs a reality check)

Let’s address the claim directly:

Bottom line: Treat “70%” as a marketing-style claim unless/until a primary source provides methodology, baseline, cohort definition, and measured endpoints.

That said, there is a very real story here: Tempus is building tooling that can compress specific steps in oncology workflows—especially those dominated by manual work, unstructured data, and coordination overhead. Those improvements can indirectly accelerate treatment start and optimize therapy selection.

Where cancer treatment time is actually lost: the operational bottlenecks AI can attack

If you want to make cancer care faster, you don’t just “do AI.” You identify where time accumulates:

  1. Eligibility discovery and trial matching (manual chart review, fragmented data, missed trials)
  2. Diagnostic and biomarker turnaround (test selection, specimen handling, rework)
  3. Pathology and tissue utilization (insufficient tissue, repeat biopsies)
  4. Clinical documentation and abstraction (unstructured notes, slow registries)
  5. Site activation and trial onboarding (process-heavy contracting and setup)
  6. Care-team coordination (alerts, referral routing, patient outreach)

Tempus’s public materials map to these choke points.

Tempus TIME Trial Network: compressing trial operations and speeding enrollment

One of the clearest, measurable Tempus claims is about trial operations speed, not “treatment time” broadly.

Tempus describes its TIME Trial Network as accelerating oncology trial processes by:

Why this matters technically

Trial enrollment delays often come down to information retrieval and workflow latency:

  • Eligibility criteria are complex and often buried in protocols.
  • Patient evidence (prior therapies, staging, biomarkers, ECOG status) is scattered across notes, pathology reports, and outside records.
  • Coordinators spend hours on chart review and cross-checking.

Generative AI-assisted pre-screening implies an NLP pipeline that:

  • Ingests unstructured clinical notes
  • Extracts structured entities (diagnosis, stage, biomarkers, prior lines, labs)
  • Maps extracted facts to trial eligibility constraints
  • Produces a “pre-screen” output for human verification

That last part—human verification—is critical in clinical settings. The speedup comes from shifting staff time from “find everything” to “review and confirm.”

Documented outcome: enrollment growth at a partner

Tempus cites a partner example: TriHealth reported a 64% annual increase in trial enrollments, with TIME driving 95% of that growth, plus improved ROI and study quality.
Source: https://www.tempus.com/oncology/clinical-trial-matching/

This isn’t a “treatment time reduced by X%” metric—but it is evidence of throughput improvement in trial enrollment, which can translate into faster patient access to novel therapies where trials are an appropriate option.

HRD-RNA algorithm: dynamic homologous recombination deficiency detection via RNA

Tempus announced a novel pan-cancer HRD-RNA algorithm, described as:

The technical implication: RNA as a functional readout

DNA-based HRD tests look for genomic “scars” (mutational signatures, LOH, etc.). RNA expression can capture a more functional, state-dependent view—potentially reflecting pathway activity and tumor biology in a way that correlates to treatment sensitivity.

From an AI standpoint, this suggests:

  • High-dimensional transcriptomic input (1,660 genes)
  • A learned mapping to an HRD likelihood score
  • A generalization challenge across tumor types (“pan-cancer”)
  • A need for strong validation to avoid confounding (batch effects, tissue composition, platform differences)

Where time gets saved (indirectly)

This doesn’t automatically shorten treatment time—what it can reduce is:

  • Time-to-right-therapy, by expanding the set of patients correctly identified for a therapy class
  • Time lost to ineffective lines, if selection improves

But again: no source here quantifies an end-to-end “70% reduction.”

Paige Predict: conserving tissue and avoiding repeat biopsies that can delay care by weeks

Tempus also highlights Paige Predict, an AI pathology tool that:

Why this is operationally significant

“Quantity not sufficient” (QNS) failures are a hidden tax in precision oncology:

  • A failed sequencing attempt triggers re-collection, re-scheduling, re-consent, and re-processing.
  • Each step carries real calendar delay plus patient burden.

An AI predictor that flags low-yield slides early enables:

  • Better specimen triage
  • Reflex workflows (e.g., choose an alternative block, adjust assay, or preemptively request more tissue)
  • Fewer reworks

This is one of the most concrete pathways to compressing timeline: preventing a “weeks-long” slip caused by QNS.

Tempus Next and Tempus One: real-time alerts, natural-language cohort building, and rapid abstraction

Tempus describes additional tools:

The technical pattern: unstructured → structured at scale

Healthcare data is notoriously messy. If you can safely extract and normalize information from:

  • Progress notes
  • Pathology narratives
  • Operative reports
  • Discharge summaries
  • Outside facility PDFs

…you unlock speed in:

  • Registry reporting
  • Cohort selection for trials
  • Quality initiatives
  • Care gaps identification
  • Retrospective reviews that inform clinical pathways

“Days vs months” is a meaningful productivity claim—especially for health systems trying to operationalize precision oncology programs.

Strategic collaboration example: NYU Langone + Tempus

Tempus also announced strategic collaborations, such as with NYU Langone, focused on:

Notably, this announcement does not quantify time savings—so treat it as evidence of investment and direction, not measured cycle-time outcomes.

The 2026 backdrop: AI in trial matching and imaging (industry-level trend)

AACR’s 2026 forecast reinforces the macro trend: AI is expected to expand its role in areas such as:

This aligns with what Tempus is building, but does not validate a specific “70%” figure.

So what can we responsibly claim? A framework for measuring real timeline reduction

Instead of repeating a viral percentage, teams should measure stage-specific cycle times. A practical measurement model:

  1. Referral → first oncology visit
  2. Order → specimen collection
  3. Specimen received → molecular result
  4. Result available → therapy decision
  5. Decision → therapy start
  6. Trial identified → pre-screen complete
  7. Pre-screen → consent
  8. Consent → enrollment

Tempus-adjacent AI capabilities can target steps 3–8. The compound effect can feel dramatic—but it’s only credible when measured stepwise with defined baselines.

Actionable takeaways: how to implement similar acceleration with AI + automation (n8n workflows)

Whether you’re a provider, payer, biotech sponsor, or digital health company, the operational playbook looks similar: integrate data, automate handoffs, and use AI where unstructured information is slowing humans down.

Below are practical, implementable patterns we deploy in AI consulting and workflow automation, including n8n workflows, to reduce latency while maintaining governance.

1) Automate clinical trial pre-screen pipelines (with human-in-the-loop)

Goal: Cut coordinator time spent on manual chart review.

Implementation pattern:

  • n8n trigger: new patient flagged (EHR event, HL7/FHIR subscription, or daily batch)
  • Pull unstructured notes and pathology reports (FHIR DocumentReference or secure document store)
  • LLM/NLP step: extract key eligibility entities (diagnosis, stage, biomarkers, prior therapies)
  • Rule layer: map entities to a trial criteria library
  • Output: ranked trial matches + “evidence snippets”
  • Human review task created in ticketing (Jira/ServiceNow) or a coordinator dashboard

Governance tip: log provenance—every extracted field should cite the source document and snippet to reduce hallucination risk.

2) Prevent QNS failures with “specimen risk scoring”

Goal: Avoid repeat biopsies that can delay treatment by weeks (as highlighted in the Paige Predict description).
Source: https://www.tempus.com/resources/content/articles/ai-in-healthcare/

Implementation pattern:

  • Ingest pathology metadata + slide images (where feasible) or lab metrics
  • Run a yield prediction model (vendor tool or internal)
  • n8n routes “high QNS risk” cases to:
    • preemptive lab consult
    • alternative sample selection
    • reflex order modifications
    • proactive patient scheduling buffer

3) Build real-time clinician alerts from unstructured signals

Goal: Speed therapy decisions and reduce missed opportunities.

Implementation pattern:

  • Stream new results/notes into an event bus (or poll)
  • NLP detects trigger events: “progression”, “new metastatic lesion”, “biomarker positive”, “eligible for PARPi”
  • n8n sends targeted alerts:
    • secure messaging to oncologist
    • task in EHR inbox
    • care coordinator work queue

This mirrors the idea of Tempus Next/One real-time alerts and unstructured insight extraction.
Source: https://www.tempus.com/resources/content/articles/ai-in-healthcare/

4) Rapid cohort building for research and quality programs

Goal: Move from months to days for cohort assembly and abstraction (similar to the 60,000-record pilot claim).
Source: https://www.tempus.com/resources/content/articles/ai-in-healthcare/

Implementation pattern:

  • Define a cohort in natural language
  • Convert to executable queries over structured + extracted-unstructured features
  • Automate periodic refresh, de-duplication, and audit trails
  • Export to REDCap, Snowflake, or sponsor portals with automated compliance checks

5) Treat biomarker AI as a product: monitoring, drift, and clinical validation

If you’re inspired by the HRD-RNA approach (RNA expression over 1,660 genes), operational readiness is as important as model performance.
Source: https://www.tempus.com/news/pr/tempus-announces-novel-pan-cancer-hrd-rna-algorithm/

Checklist for teams:

  • Data lineage (sample → sequencing → normalization → inference)
  • Batch-effect detection and mitigation
  • Model monitoring (drift, calibration, subgroup performance)
  • Clinical governance (who signs off, when, and how results are communicated)

What this means for business leaders: speed is a systems problem, not a model problem

The biggest misconception in “AI reduces time by X%” stories is assuming AI alone drives the improvement. In reality, cycle-time reduction comes from:

  • Integration (EHR/LIS/RIS, lab vendors, trial databases)
  • Orchestration (workflow automation, queues, routing, SLAs)
  • Human-in-the-loop design (review surfaces, evidence highlighting)
  • Measurement (stage-level baselines, continuous improvement)
  • Compliance and security (HIPAA, least privilege, audit logs)

Tempus’s public narrative strongly reflects this systems view: AI embedded into trial networks, pathology workflows, and clinical insight tools—not AI in isolation.

Conclusion: the “70% in 2026” headline is unverified—but the underlying acceleration is real and implementable

To be precise: reputable sources do not confirm that “Tempus AI cuts cancer treatment time by 70% in 2026.” What they do document are credible levers that reduce delays:

If your organization wants comparable gains, the most reliable path is to instrument and automate the care and trial pipeline end-to-end—measuring each stage, applying AI where unstructured data creates bottlenecks, and orchestrating actions with secure, auditable automation.

Call to action: accelerate your oncology workflows with AI + n8n automation

If you’re evaluating AI for oncology operations—trial matching, cohort building, pathology workflow optimization, or real-time clinical alerts—we can help you turn promising tools into production-grade, measurable time savings.

Contact us to discuss:

  • An AI readiness assessment for unstructured clinical data
  • Secure LLM/NLP pipelines with human-in-the-loop verification
  • n8n workflow orchestration across EHR/LIS, trial databases, and care coordination tools
  • KPI design to quantify cycle-time reductions without over-claiming outcomes

Reach out to explore our AI consulting and workflow automation services and map your fastest path from pilot to impact.}